Cancer Immunotherapy Market - 2024-2033
The Cancer Immunotherapy Market was valued at US$ 137.70 billion in 2024 and is anticipated to reach US$ 261.74 billion by 2033, at a CAGR of 0.079 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Cancer Immunotherapy Market.
This report delivers a comprehensive overview of the Cancer Immunotherapy Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Cancer Immunotherapy Market. The Cancer Immunotherapy Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.
Cancer Immunotherapy Market Scope:
Major Highlights
This report delivers a comprehensive overview of the Cancer Immunotherapy Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Cancer Immunotherapy Market. The Cancer Immunotherapy Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Cancer Immunotherapy Market.
This report delivers a comprehensive overview of the Cancer Immunotherapy Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Cancer Immunotherapy Market. The Cancer Immunotherapy Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.
Cancer Immunotherapy Market Scope:
Major Highlights
This report delivers a comprehensive overview of the Cancer Immunotherapy Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Cancer Immunotherapy Market. The Cancer Immunotherapy Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Increase Your Customer Base by 3X using our Partner Identification tool
- Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
- Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
- Prioritize partners by strategic fit rather than general capability.
- Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
- Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
- White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
- Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
- Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
- Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS
3.1. Key Trends and Future Projections
4. SNIPPET BY TYPE
4.1. Snippet by Indication
5. SNIPPET BY REGION
6. DYNAMICS
6.1. Impacting Factors
6.1.1. Drivers
6.1.1.1. Rising Incidence and Prevalence of Cancer
7. RISING NOVEL IMMUNOTHERAPY DEVELOPMENT ACTIVITIES AND APPROVALS
8. RESTRAINTS
8.1. High Cost of Immunotherapies
9. PATIENT ADHERENCE AND COMPLIANCE ISSUES
10. OPPORTUNITIES
10.1. Rising Demand from Emerging Countries
10.1.1. Impact Analysis
11. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
11.1. Epidemiology
11.2. Market Leaders and Pioneers
11.3. Latest Developments and Breakthroughs
11.4. Pipeline Analysis
11.5. Regulatory and Reimbursement Landscape
11.6. Pricing Analysis
11.7. Porter’s Five Forces Analysis
11.8. Patent Analysis
11.9. SWOT Analysis
11.10. Unmet Needs and Gaps
11.11. Recommended Strategies for Market Entry and Expansion
11.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
12. GLOBAL CANCER IMMUNOTHERAPY MARKET, BY TYPE
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.1.2. Market Attractiveness Index, By Type
12.2. Immune Checkpoint Inhibitors*
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.2.3. Pembrolizumab
12.2.4. Atezolizumab
12.2.5. Avelumab
12.2.6. Nivolumab
12.2.7. Durvalumab
12.2.8. Ipilimumab
12.2.9. Others
12.3. Cytokines
12.4. Cancer Vaccines
12.5. Adoptive Cell Therapy
12.5.1. Tumor Infiltrating Lymphocyte (TIL) Therapy
12.5.2. Engineered T-Cell Receptor (TCR) Therapy
12.5.3. Chimeric Antigen Receptor (CAR) T Cell Therapy
12.5.4. Natural Killer (NK) Cell Therapy
12.6. Other Immunotherapies
13. GLOBAL CANCER IMMUNOTHERAPY MARKET, BY INDICATION
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
13.1.2. Market Attractiveness Index, By Indication
13.2. Non-Small Cell Lung Cancer (NSCLC)*
13.2.1. Introduction
13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
13.3. Melanoma
13.4. Colorectal Cancer
13.5. Renal Cell Carcinoma
13.6. Breast Cancer
13.7. Bladder Cancer
13.8. Others
14. GLOBAL CANCER IMMUNOTHERAPY MARKET, BY REGION
14.1. Introduction
14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
14.1.2. Market Attractiveness Index, By Region
14.2. North America
14.2.1. Introduction
14.2.2. Key Region-Specific Dynamics
14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.2.5.1. U.S.
14.2.5.2. Canada
14.2.5.3. Mexico
14.3. Europe
14.3.1. Introduction
14.3.2. Key Region-Specific Dynamics
14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.3.5.1. Germany
14.3.5.2. U.K.
14.3.5.3. France
14.3.5.4. Spain
14.3.5.5. Italy
14.3.5.6. Rest of Europe
14.4. South America
14.4.1. Introduction
14.4.2. Key Region-Specific Dynamics
14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.4.5.1. Brazil
14.4.5.2. Argentina
14.4.5.3. Rest of South America
14.5. Asia-Pacific
14.5.1. Introduction
14.5.2. Key Region-Specific Dynamics
14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.5.5.1. China
14.5.5.2. India
14.5.5.3. Japan
14.5.5.4. South Korea
14.5.5.5. Rest of Asia-Pacific
14.6. Middle East and Africa
14.6.1. Introduction
14.6.2. Key Region-Specific Dynamics
14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
15. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
15.1. Competitive Overview and Key Market Players
15.2. Market Share Analysis and Positioning Matrix
15.3. Strategic Partnerships, Mergers & Acquisitions
15.4. Key Developments in Product Portfolios and Innovations
15.5. Company Benchmarking
16. COMPANY PROFILES
Key Market Players
1. MERCK & CO., INC.*
1.1. Company Overview
1.1.1. Product Portfolio
1.1.1.1. Product Description
1.1.1.2. Product Key Performance Indicators (KPIs)
1.1.1.3. Historic and Forecasted Product Sales
1.1.1.4. Product Sales Volume
1.1.2. Financial Overview
1.1.2.1. Company Revenue’s
1.1.2.2. Geographical Revenue Shares
1.1.2.3. Revenue Forecasts
1.1.3. Key Developments
1.1.3.1. Mergers & Acquisitions
1.1.3.2. Key Product Development Activities
1.1.3.3. Regulatory Approvals, etc.
1.1.4. SWOT Analysis
1.2. Johnson & Johnson Services, Inc.
1.3. Bristol-Myers Squibb Company
1.4. AstraZeneca
1.5. Pfizer Inc.
1.6. F. Hoffmann-La Roche Ltd
1.7. Novartis AG
1.8. Kite Pharma, Inc.
1.9. Dendreon Pharmaceuticals LLC.
1.10. Amgen Inc. (*THE LIST IS NOT EXHAUSTIVE)
2. APPENDIX
2.1. About Us and Services
2.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS
3.1. Key Trends and Future Projections
4. SNIPPET BY TYPE
4.1. Snippet by Indication
5. SNIPPET BY REGION
6. DYNAMICS
6.1. Impacting Factors
6.1.1. Drivers
6.1.1.1. Rising Incidence and Prevalence of Cancer
7. RISING NOVEL IMMUNOTHERAPY DEVELOPMENT ACTIVITIES AND APPROVALS
8. RESTRAINTS
8.1. High Cost of Immunotherapies
9. PATIENT ADHERENCE AND COMPLIANCE ISSUES
10. OPPORTUNITIES
10.1. Rising Demand from Emerging Countries
10.1.1. Impact Analysis
11. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
11.1. Epidemiology
11.2. Market Leaders and Pioneers
11.3. Latest Developments and Breakthroughs
11.4. Pipeline Analysis
11.5. Regulatory and Reimbursement Landscape
11.6. Pricing Analysis
11.7. Porter’s Five Forces Analysis
11.8. Patent Analysis
11.9. SWOT Analysis
11.10. Unmet Needs and Gaps
11.11. Recommended Strategies for Market Entry and Expansion
11.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
12. GLOBAL CANCER IMMUNOTHERAPY MARKET, BY TYPE
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.1.2. Market Attractiveness Index, By Type
12.2. Immune Checkpoint Inhibitors*
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.2.3. Pembrolizumab
12.2.4. Atezolizumab
12.2.5. Avelumab
12.2.6. Nivolumab
12.2.7. Durvalumab
12.2.8. Ipilimumab
12.2.9. Others
12.3. Cytokines
12.4. Cancer Vaccines
12.5. Adoptive Cell Therapy
12.5.1. Tumor Infiltrating Lymphocyte (TIL) Therapy
12.5.2. Engineered T-Cell Receptor (TCR) Therapy
12.5.3. Chimeric Antigen Receptor (CAR) T Cell Therapy
12.5.4. Natural Killer (NK) Cell Therapy
12.6. Other Immunotherapies
13. GLOBAL CANCER IMMUNOTHERAPY MARKET, BY INDICATION
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
13.1.2. Market Attractiveness Index, By Indication
13.2. Non-Small Cell Lung Cancer (NSCLC)*
13.2.1. Introduction
13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
13.3. Melanoma
13.4. Colorectal Cancer
13.5. Renal Cell Carcinoma
13.6. Breast Cancer
13.7. Bladder Cancer
13.8. Others
14. GLOBAL CANCER IMMUNOTHERAPY MARKET, BY REGION
14.1. Introduction
14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
14.1.2. Market Attractiveness Index, By Region
14.2. North America
14.2.1. Introduction
14.2.2. Key Region-Specific Dynamics
14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.2.5.1. U.S.
14.2.5.2. Canada
14.2.5.3. Mexico
14.3. Europe
14.3.1. Introduction
14.3.2. Key Region-Specific Dynamics
14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.3.5.1. Germany
14.3.5.2. U.K.
14.3.5.3. France
14.3.5.4. Spain
14.3.5.5. Italy
14.3.5.6. Rest of Europe
14.4. South America
14.4.1. Introduction
14.4.2. Key Region-Specific Dynamics
14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.4.5.1. Brazil
14.4.5.2. Argentina
14.4.5.3. Rest of South America
14.5. Asia-Pacific
14.5.1. Introduction
14.5.2. Key Region-Specific Dynamics
14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.5.5.1. China
14.5.5.2. India
14.5.5.3. Japan
14.5.5.4. South Korea
14.5.5.5. Rest of Asia-Pacific
14.6. Middle East and Africa
14.6.1. Introduction
14.6.2. Key Region-Specific Dynamics
14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
15. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
15.1. Competitive Overview and Key Market Players
15.2. Market Share Analysis and Positioning Matrix
15.3. Strategic Partnerships, Mergers & Acquisitions
15.4. Key Developments in Product Portfolios and Innovations
15.5. Company Benchmarking
16. COMPANY PROFILES
Key Market Players
1. MERCK & CO., INC.*
1.1. Company Overview
1.1.1. Product Portfolio
1.1.1.1. Product Description
1.1.1.2. Product Key Performance Indicators (KPIs)
1.1.1.3. Historic and Forecasted Product Sales
1.1.1.4. Product Sales Volume
1.1.2. Financial Overview
1.1.2.1. Company Revenue’s
1.1.2.2. Geographical Revenue Shares
1.1.2.3. Revenue Forecasts
1.1.3. Key Developments
1.1.3.1. Mergers & Acquisitions
1.1.3.2. Key Product Development Activities
1.1.3.3. Regulatory Approvals, etc.
1.1.4. SWOT Analysis
1.2. Johnson & Johnson Services, Inc.
1.3. Bristol-Myers Squibb Company
1.4. AstraZeneca
1.5. Pfizer Inc.
1.6. F. Hoffmann-La Roche Ltd
1.7. Novartis AG
1.8. Kite Pharma, Inc.
1.9. Dendreon Pharmaceuticals LLC.
1.10. Amgen Inc. (*THE LIST IS NOT EXHAUSTIVE)
2. APPENDIX
2.1. About Us and Services
2.2. Contact Us
